Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Leukemia. 2013 Jun 13;27(12):2385–2388. doi: 10.1038/leu.2013.175

Figure 2.

Figure 2

Galectin-3 protects ALL cells against drug treatment. (a) TXL2-pMIG, TXL2-pMIG-Gal3 and TXL2-pMIG-Gal3S6A cells cultured without OP9 cells over a 3-day period. Apoptosis was measured using FACS (*P<0.05, **P<0.01). (b, c) TXL2 cells transduced with pMIG, pMIG-Gal3 or pMIG-Gal3S6A were treated with nilotinib (b) or vincristine (c). (d) Analysis of signal transduction in gal3 +/+ and gal3 −/− pre-B ALL cells as detected by western blot. Cells were grown without stroma. (e, f) Comparison of viable cell counts of gal3 +/+ and gal3 −/− pre-B ALL cells treated with nilotinib (e) or vincristine (f) for 72 h. Viable cells were counted by Trypan blue exclusion assay. Results shown are from one of three independent experiments with similar results.